Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been newly diagnosed with a specific type of lung cancer called limited-stage small cell lung cancer (LS-SCLC), confirmed by a lab test from a tissue or cell sample.
• You were treated with chemotherapy and radiation therapy given one after the other (not at the same time), or with chemotherapy alone.
• You have at least one area of cancer that can be tracked or measured using standard imaging guidelines.
• Your cancer has not gotten worse after completing your chemotherapy or chemo-radiation treatment.
• You are 18 years of age or older.
• You are expected to live for at least 3 months from the start of the study.
• You are well enough to carry out daily activities, as assessed by a standard health scoring tool, within 7 days before your first dose.
• Side effects from your previous treatment have mostly cleared up (reduced to a mild level or less).
• Your heart rhythm test (ECG) shows no significant problems.
• Your lungs are working well enough that you do not need extra oxygen.
• You are willing and able to give written consent to take part in the study.
• Your blood tests and organ function results (such as kidney and liver) are within acceptable ranges.

Who may not be able to join:

• You need additional radiation therapy as part of your current LS-SCLC treatment.
• You have extensive-stage small cell lung cancer, a history of another type of lung cancer that changed into small cell lung cancer, or a mixed tumor type.
• You have a known history of, or currently have, a nervous system condition related to your cancer that involves the immune system (confirm with trial site).
• You have had major surgery within the 4 weeks before your first study dose.
• You have taken part in another clinical trial or used an experimental medical device within the 4 weeks before your first study dose.
• You have a history of a second type of cancer (other than this lung cancer), unless you completed potentially curative treatment with no signs of cancer for at least 3 years.
• You have an active infection that is not controlled and currently requires medication.
• You have a lung condition called interstitial lung disease or active non-infectious lung inflammation.
• You have previously had an organ transplant.
• You have had a heart attack or significant heart failure within the 6 months before your first study dose.
• You have a known history of HIV infection.
• You have a known history of Hepatitis B, or a currently active Hepatitis C infection.
• You have a known history of active tuberculosis.
• You have any other health condition, treatment history, or lab result that the trial doctor feels could affect the study results or your safety (confirm with trial site).
• You have a known psychiatric condition or substance use disorder that could make it difficult to follow the trial requirements.
• You have a serious wound, ulcer, or bone fracture that has not healed within 28 days before your first study dose.
• You are a woman who could become pregnant and are unwilling to use the required contraception during treatment and for 60 days after your last dose.
• You are currently breastfeeding or plan to breastfeed during the study and for 60 days after your last dose.
• You are planning to become pregnant or donate eggs during the study or within 60 days after your last dose.
• You are a woman who could become pregnant and have a positive pregnancy test at screening.
• You are a man with a female partner who could become pregnant and are unwilling to use contraception or abstain from sex during treatment and for 60 days after your last dose.
• You are a man whose partner is pregnant and you are unwilling to abstain from sex or use a condom during treatment and for 60 days after your last dose.
• You have a known allergy or sensitivity to any of the products used in this study.

Important: Always verify eligibility with the trial site directly before applying.